Janux Therapeutics is a biopharmaceutical company engaged in the dvelopment of next-generation therapeutics based on Co.'s proprietary Tumor Activated T Cell Engager ("TRACTr") platform technology to better treat patients suffering from cancer. Co.'s initial focus is on developing a novel class of T cell engagers ("TCEs"), and Co.'s lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors has faced challenges due to the limitations of prior TCE technologies. The JANX stock yearly return is shown above.
The yearly return on the JANX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the JANX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|